You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt | 0 | 3,732,414 | 0 | 3,732,414 | 3,732,414 | 23.84% |
| Deerfield Special Situations Fund | 0 | 1,124,740 | 0 | 1,124,740 | 1,124,740 | 7.18% |
| Deerfield Private Design International | 0 | 647,152 | 0 | 647,152 | 647,152 | 4.13% |
| Deerfield Private Design Fund II | 0 | 726,242 | 0 | 726,242 | 726,242 | 4.64% |
| Deerfield Private Design International II | 0 | 832,216 | 0 | 832,216 | 832,216 | 5.32% |
| Deerfield Management Company | 0 | 3,741,639 | 0 | 3,741,639 | 3,741,639 | 23.89% |
| Deerfield Private Design Fund | 0 | 402,064 | 0 | 402,064 | 402,064 | 2.57% |
| James E. Flynn | 0 | 3,741,639 | 0 | 3,741,639 | 3,741,639 | 23.89% |
Page 1 of 16 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
[Rule 13d-101]
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §
24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a)
(Amendment No. 2)*
Nivalis
Therapeutics, Inc.
(Name
of Issuer)
Common
Stock, par value $0.001 per share
(Title
of Class of Securities)
65481J109
(CUSIP
Number)
| David Deerfield 780 New (212) 551-1600 With a copy to: Mark Jonathan Katten 575 New (212) 940-8800 |
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
April
17, 2017
(Date
of Event which Requires Filing of this Statement)
If the filing person
has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7
for other parties to whom copies are to be sent.
(Continued on following
pages)
(Page 1 of 15 Pages)
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
